The chair is funded by the healthcare solutions company Navvis.
Thomas Jefferson University’s College of Population Health today announced that the healthcare management company Navvis will fund an endowed chair in population health, the first privately supported academic chair in the discipline in the country.
The Navvis Professorship of Population Health, funded with $2 million, will support the work of a faculty member devoted to national research that examines which healthcare interventions work best in the real world.
Officials from Thomas Jefferson University, located in Philadelphia, Pennsylvania, said the funding of the position represents “a shift in thinking regarding ways to improve health and reduce healthcare costs.” A statement said the endowed chair is part of broader partnership between university and the company, which seeks to address overlapping patient needs by delivering seamless, aligned provider networks.
"Along with our academic and primary research with our partners at Jefferson, we are building ecosystems that break down silos and provide care for the real-world needs of people," said Navvis Chairman and CEO Mike Farris in the statement. "The Navvis Professorship of Population Health represents our commitment to life-changing healthcare--improving the everyday interactions that people have with their health."
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More